White House Domestic Policy Council Director Joe Grogan is departing at the end of May. In an interview, he talked about lessons (so far) from the COVID-19 response and the future of drug pricing policy against the backdrop of the pandemic.

Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.

Eric Bastings will lead Division of Neurology I, which is expected to handle Biogen’s Alzheimer’s drug aducanumab and Sarepta’s refiling of golodirsen for DMD next year.

Senate Majority Leader McConnell is the one constant keeping drug price controls from gaining any legislative traction.

The rebate rule is dead, but we should pay tribute to the failed endeavor.

Price justification legislation is advancing in both chambers of Congress. But CBO scores them as no savings.